Biliary-Pancreas research team
Our laboratory is investigating the mechanisms of resistance to chemotherapy in pancreatic cancer and cholangiocarcinoma and the way how to overcome chemoresistance by regulation of expression of miRNAs (including miR-21) using natural compounds. Our studies also focus on predictors of adjuvant treatment responsiveness in pancreatic cancers. We are trying to identify diabetes-related diagnostic serum biomarkers in pancreatic cancer (using high-throughput tech) and to validate its clinical usefulness as a potential clue to the early diagnosis of pancreatic cancer. We are developing novel biomarkers that can predict pancreatic cancer recurrence and are studying the mechanism including EMT (epithelial-mesenchymal transition) using human orthotopic pancreatic cancer model as well. In addition to our translational research, we are planning to conduct phase I trial of gene therapy using adenoviral vector for local control of locally advanced pancreatic cancer. We are also focusing on clinical studies about cholangiocarcinoma, GB cancer, pancreatitis, gallstone disease, ERCP and EUS.
췌장암은 진단초기에 전이가 일어나고 수술적 완전절제가 이루어 진 후에도 대부분의 환자가 재발을 경험하기 때문에 전이 및 재발기전에 대한 연구도 매우 중요합니다. 이 과정에 EMT (epithelial-mesenchymal transition)가 관여하는데 (그림), 본 연구실에서는 수술 후 재발에 관여하는 분자생물학적 마커를 개발하고자 연구를 진행하고 있습니다.
